Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy

被引:80
作者
Jabs, DA
Holbrook, JT
Van Natta, ML
Clark, R
Jacobson, MA
Kempen, JH
Murphy, RL
机构
[1] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD USA
[2] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD USA
[3] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[4] Louisiana State Univ, Sch Med, Dept Med, New Orleans, LA USA
[5] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[6] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
关键词
D O I
10.1016/j.ophtha.2004.10.049
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To evaluate risk factors for mortality among patients with AIDS in the era of highly active antiretroviral therapy (HAART), particularly the effect of cytomegalovirus (CMV). Design: Prospective cohort study of patients with AIDS, conducted from 1998 through 2003. Participants: One thousand five hundred eighty-three patients with AIDS, of whom 374 had CMV retinitis. Methods: Patients were contacted every 3 months, with examinations at least every 6 months, in which standardized data were collected on AIDS history and treatment, eye examinations, and hematologic, virologic, and immunologic laboratory data. Main Outcome Measure: Mortality. Results: The overall mortality rate was 0.07 deaths/person -year. In a multivariate analysis, the following baseline risk factors were associated with an increased mortality: higher human immunodeficiency virus (HIV) viral load (relative risk [RR] = 4.6 for HIV viral load > 1 00 000 copies/ml vs. < 400 copies/ml; P < 0.0001), lower CD4+ T-cell count at enrollment (RR = 3.8 for CD4+ T cell count 0-49 cells/mu l vs.; >= 200 cells/bLI; P < 0.0001), CMV viral load >= 400 copies/ml (RR = 1.9; P = 0.002), lower hemoglobin (RR = 1.7 for hemoglobin < 10 g/dl; P = 0.009), a history of cryptococcal meningitis (RR = 1.7; P = 0.02), CMV retinitis (RR = 1.6; P = 0.0002), and Karnofsky score <= 80 (RR = 1.4; P = 0.008). Conclusions: In the era of HAART, CMV disease as manifested by CMV retinitis and a detectable CMV viral load were associated with an increased risk for mortality, even after adjusting for demographic, treatment, immunologic, and HIV virologic factors. (c) 2005 by the American Academy of Ophthalmology.
引用
收藏
页码:771 / 779
页数:9
相关论文
共 56 条
[11]  
Jabs D A, 1995, Trans Am Ophthalmol Soc, V93, P623
[12]  
JABS DA, 1992, NEW ENGL J MED, V326, P213, DOI 10.1056/NEJM199201233260401
[13]   AIDS and ophthalmology: A period of transition [J].
Jabs, DA ;
Bartlett, JG .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1997, 124 (02) :227-233
[14]   Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy [J].
Jabs, DA ;
Bolton, SG ;
Dunn, JP ;
Palestine, AG .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1998, 126 (06) :817-822
[15]   Comparison of cytomegalovirus loads in plasma and leukocytes of patients with cytomegalovirus retinitis [J].
Jabs, DA ;
Forman, M ;
Enger, C ;
Jackson, JB .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (05) :1431-1435
[16]   Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy [J].
Jabs, DA ;
van Natta, ML ;
Kempen, JH ;
Pavan, PR ;
Lim, JI ;
Murphy, RL ;
Hubbard, LD .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2002, 133 (01) :48-61
[17]   The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: The ganciclovir cidofovir cytomegalovirus retinitis trial [J].
Jabs, DA .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2001, 131 (04) :457-467
[18]   Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy [J].
Jacobson, MA ;
Stanley, H ;
Holtzer, C ;
Margolis, TP ;
Cunningham, ET .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (01) :231-233
[19]  
Kaplan Jonathan E, 2002, MMWR Recomm Rep, V51, P1
[20]  
KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO